<!DOCTYPE html>
<html lang="en">
<head>
 <meta charset="UTF-8">
 <meta name="viewport" content="width=device-width, initial-scale=1.0">
 <title>Lesson 5: Cardiovascular Risk Assessment in the Post-Menopausal 'Evolve' Phase | AccrediPro Academy</title>
 <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700;800&display=swap" rel="stylesheet">
 <style>
/* ===========================================
 ACCREDIPRO GOLD STANDARD - UNIFIED LESSON CSS v5.0
 School-Quality ‚Ä¢ ASI Certified ‚Ä¢ Premium UX
 =========================================== */

/* Reset & Base */
* {
 box-sizing: border-box;
 margin: 0;
 padding: 0;
}

body {
 font-family: 'Inter', -apple-system, BlinkMacSystemFont, sans-serif;
 line-height: 1.8;
 color: #1f2937;
 background: #ffffff;
 font-size: 17px;
}

/* MAIN WRAPPER */
.lesson-wrapper {
 max-width: 1200px;
 margin: 0 auto;
 padding: 40px 20px;
}

/* HEADER CARD - Premium Gradient */
.module-header-card {
 background: linear-gradient(135deg, #722F37 0%, #722F37 50%, #5a252b 100%);
 padding: 48px 40px;
 margin-bottom: 40px;
 border-radius: 24px;
 box-shadow: 0 20px 60px -15px rgba(114, 47, 55, 0.4);
 border: none;
 text-align: center;
 position: relative;
 overflow: hidden;
}

.module-header-card::before {
 content: '';
 position: absolute;
 top: -50%;
 left: -50%;
 width: 200%;
 height: 200%;
 background: radial-gradient(circle, rgba(255, 255, 255, 0.05) 0%, transparent 70%);
 pointer-events: none;
}

.module-label {
 font-size: 12px;
 text-transform: uppercase;
 letter-spacing: 3px;
 color: rgba(255, 255, 255, 0.8);
 margin-bottom: 12px;
 font-weight: 600;
 display: block;
}

.lesson-title {
 font-size: 38px;
 color: #ffffff;
 font-weight: 800;
 margin: 0 0 20px 0;
 line-height: 1.15;
 text-shadow: 0 2px 4px rgba(0, 0, 0, 0.1);
}

/* META BADGES */
.lesson-meta {
 display: flex;
 justify-content: center;
 gap: 12px;
 flex-wrap: wrap;
}

.meta-badge {
 background: rgba(255, 255, 255, 0.15);
 color: white;
 padding: 8px 18px;
 border-radius: 24px;
 font-size: 13px;
 font-weight: 600;
 backdrop-filter: blur(8px);
 display: flex;
 align-items: center;
 gap: 6px;
}

/* ASI CREDENTIAL STRIP */
.asi-credential-strip {
 background: linear-gradient(90deg, #f8f5f0, #fffbeb, #f8f5f0);
 border: 1px solid #e5d9c3;
 border-radius: 12px;
 padding: 16px 24px;
 margin-bottom: 32px;
 display: flex;
 align-items: center;
 gap: 16px;
}

.asi-logo {
 width: 48px;
 height: 48px;
 background: linear-gradient(135deg, #B8860B, #D4A813);
 border-radius: 10px;
 display: flex;
 align-items: center;
 justify-content: center;
 font-size: 24px;
 color: white;
 flex-shrink: 0;
 box-shadow: 0 4px 12px rgba(184, 134, 11, 0.25);
}

.asi-text {
 flex: 1;
}

.asi-text .label {
 font-size: 11px;
 text-transform: uppercase;
 letter-spacing: 1px;
 color: #92400e;
 font-weight: 700;
}

.asi-text .title {
 font-size: 15px;
 color: #78350f;
 font-weight: 600;
 margin-top: 2px;
}

/* TABLE OF CONTENTS */
.toc-box {
 background: transparent;
 border: none;
 border-radius: 0;
 padding: 0;
 margin-bottom: 40px;
}

.toc-label {
 font-size: 11px;
 text-transform: uppercase;
 letter-spacing: 1.5px;
 color: #6b7280;
 font-weight: 700;
 margin-bottom: 16px;
 display: block;
}

.toc-list {
 list-style: none;
 display: grid;
 grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
 gap: 8px;
}

.toc-list li a {
 display: flex;
 align-items: center;
 gap: 10px;
 padding: 10px 14px;
 background: #f9fafb;
 border: none;
 border-radius: 8px;
 text-decoration: none;
 color: #374151;
 font-size: 14px;
 font-weight: 500;
 transition: all 0.2s;
}

.toc-list li a:hover {
 background: #f3f4f6;
 color: #722F37;
 transform: translateX(4px);
}

.section-num {
 background: #722F37;
 color: white;
 width: 24px;
 height: 24px;
 border-radius: 6px;
 display: flex;
 align-items: center;
 justify-content: center;
 font-size: 11px;
 font-weight: 700;
 flex-shrink: 0;
}

/* WELCOME BOX */
.welcome-box {
 background: linear-gradient(135deg, #fefbf3 0%, #f8f5f0 100%);
 padding: 28px;
 margin-bottom: 40px;
 border-radius: 16px;
 border-left: 5px solid #B8860B;
 box-shadow: 0 4px 12px rgba(0, 0, 0, 0.04);
}

.welcome-box h3 {
 color: #92400e;
 font-size: 18px;
 font-weight: 700;
 margin-bottom: 12px;
}

/* OBJECTIVES BOX */
.objectives-box {
 background: linear-gradient(135deg, #faf5ff 0%, #f3e8ff 100%);
 border-radius: 16px;
 padding: 28px;
 margin-bottom: 40px;
 border: 1px solid #e9d5ff;
}

.box-label {
 font-weight: 700;
 color: #722F37;
 text-transform: uppercase;
 letter-spacing: 1px;
 font-size: 12px;
 margin-bottom: 16px;
 display: block;
}

.objectives-box ul {
 list-style: none;
 margin: 0;
 padding: 0;
}

.objectives-box li {
 padding: 10px 0 10px 32px;
 position: relative;
 font-size: 16px;
 color: #4c1d95;
 border-bottom: 1px solid rgba(167, 139, 250, 0.2);
}

.objectives-box li::before {
 content: '‚úì';
 position: absolute;
 left: 0;
 color: #7c3aed;
 font-weight: 700;
}

/* HIGHLIGHT */
.highlight {
 background: linear-gradient(120deg, #fef3c7 0%, #fef3c7 100%);
 padding: 1px 6px;
 border-radius: 4px;
 font-weight: 600;
 color: inherit;
}

/* TYPOGRAPHY */
h2 {
 color: #722F37;
 font-size: 28px;
 margin: 56px 0 24px 0;
 font-weight: 800;
 position: relative;
 padding-bottom: 16px;
}

h2::after {
 content: '';
 position: absolute;
 bottom: 0;
 left: 0;
 width: 60px;
 height: 4px;
 background: linear-gradient(90deg, #B8860B, #D4A813);
 border-radius: 2px;
}

h3 {
 color: #722F37;
 font-size: 22px;
 margin: 36px 0 16px 0;
 font-weight: 700;
}

p {
 font-size: 17px;
 line-height: 1.85;
 color: #374151;
 margin-bottom: 20px;
}

/* CASE STUDY */
.case-study {
 background: white;
 border-radius: 20px;
 margin: 40px 0;
 border: 1px solid #e5e7eb;
 box-shadow: 0 8px 30px rgba(0, 0, 0, 0.06);
 overflow: hidden;
}

.case-study-header {
 background: linear-gradient(90deg, #722F37, #722F37);
 padding: 20px 28px;
 display: flex;
 align-items: center;
 gap: 16px;
}

.case-study-icon {
 width: 48px;
 height: 48px;
 background: rgba(255, 255, 255, 0.2);
 border-radius: 12px;
 display: flex;
 align-items: center;
 justify-content: center;
 font-size: 24px;
}

.case-study-header .title {
 color: white;
 font-weight: 700;
 font-size: 16px;
 margin: 0;
}

.case-study-content {
 padding: 28px;
}

.patient-profile {
 background: #f9fafb;
 padding: 20px;
 border-radius: 12px;
 margin-bottom: 20px;
}

/* DATA TABLE */
.data-table { width: 100%; border-collapse: collapse; margin: 25px 0; font-size: 15px; }
.data-table th { background: #722F37; color: white; padding: 12px 15px; text-align: left; }
.data-table td { padding: 12px 15px; border-bottom: 1px solid #e5e7eb; }
.data-table tr:nth-child(even) { background: #f9fafb; }

/* COACH TIP BOX */
.coach-tip {
 background: linear-gradient(135deg, #fefce8 0%, #fef9c3 100%);
 border: 1px solid #fde047;
 border-radius: 16px;
 padding: 24px 28px;
 margin: 32px 0;
 position: relative;
}

.coach-tip::before {
 content: 'üí°';
 position: absolute;
 top: -12px;
 left: 24px;
 background: white;
 padding: 4px 8px;
 border-radius: 8px;
 font-size: 20px;
 box-shadow: 0 2px 8px rgba(0,0,0,0.08);
}

.coach-tip .tip-label {
 font-size: 11px;
 text-transform: uppercase;
 letter-spacing: 1.5px;
 color: #a16207;
 font-weight: 700;
 margin-bottom: 8px;
 display: block;
}

/* CHECK YOUR UNDERSTANDING */
.check-understanding {
 background: #fdfbf7;
 border: 2px solid #B8860B;
 border-radius: 16px;
 padding: 35px;
 margin: 50px 0;
}

.check-understanding .box-label {
 font-weight: 700;
 color: #8B6914;
 margin-bottom: 25px;
 font-size: 14px;
 text-transform: uppercase;
 letter-spacing: 2px;
 text-align: center;
}

.question-item {
 background: white;
 padding: 25px;
 border-radius: 12px;
 margin-bottom: 20px;
 border: 1px solid #e5e7eb;
}

.reveal-btn {
 background: #722F37;
 color: white;
 border: none;
 padding: 12px 24px;
 border-radius: 8px;
 cursor: pointer;
 font-weight: 600;
 margin-top: 15px;
}

.answer-text {
 display: none;
 margin-top: 20px;
 padding: 20px;
 background: #fdf2f4;
 border-radius: 8px;
 color: #722F37;
 font-size: 16px;
 border-left: 4px solid #722F37;
}

/* KEY TAKEAWAYS */
.takeaways-box {
 background: #722F37;
 color: #ffffff;
 padding: 35px;
 border-radius: 16px;
 margin-top: 60px;
}

.takeaways-box .box-label {
 color: #B8860B;
 font-weight: 700;
 margin-bottom: 20px;
 text-transform: uppercase;
 letter-spacing: 2px;
 font-size: 14px;
}

.takeaways-box ul {
 margin: 0;
 padding-left: 20px;
}

.takeaways-box li {
 margin-bottom: 12px;
 color: #ffffff;
}

/* REFERENCES */
.references-box {
 background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);
 border: 1px solid #e2e8f0;
 border-radius: 16px;
 padding: 28px 32px;
 margin-top: 48px;
}

.references-box .box-label {
 color: #64748b;
 font-size: 12px;
 text-transform: uppercase;
 letter-spacing: 1.5px;
 font-weight: 700;
 margin-bottom: 16px;
}

.references-box ol {
 list-style: none;
 padding: 0;
}

.references-box li {
 padding: 12px 16px 12px 48px;
 position: relative;
 font-size: 14px;
 color: #475569;
 background: white;
 border-radius: 8px;
 margin-bottom: 8px;
 border: 1px solid #e5e7eb;
}

.references-box li::before {
 content: '';
 position: absolute;
 left: 16px;
 top: 12px;
 width: 22px;
 height: 22px;
 background: #722F37;
 color: white;
 border-radius: 50%;
}

.stat-highlight {
 font-weight: 800;
 color: #722F37;
}

.module-connection {
 background: linear-gradient(135deg, #f0f9ff 0%, #e0f2fe 100%);
 border: 1px solid #7dd3fc;
 border-radius: 16px;
 padding: 20px 24px;
 margin-bottom: 32px;
 display: flex;
 align-items: center;
 gap: 16px;
}
</style>
</head>
<body>

<div class="lesson-wrapper">
 <!-- Module Header Card -->
 <div class="module-header-card">
 <span class="module-label">Module 13: Advanced Clinical Deep Dives</span>
 <h1 class="lesson-title">Cardiovascular Risk Assessment in the Post-Menopausal 'Evolve' Phase</h1>
 <div class="lesson-meta">
 <span class="meta-badge">‚è±Ô∏è 15 min read</span>
 <span class="meta-badge">üí° Lesson 5 of 8</span>
 </div>
 </div>

 <!-- ASI Credential Strip -->
 <div class="asi-credential-strip">
 <div class="asi-logo">ASI</div>
 <div class="asi-text">
 <div class="label">Verified Credential</div>
 <div class="title">AccrediPro Standards Institute‚Ñ¢ Certified Content</div>
 </div>
 </div>

 <!-- Table of Contents -->
 <nav class="toc-box">
 <p class="toc-label">In This Lesson</p>
 <ul class="toc-list">
 <li><a href="#cardiovascular-cliff"><span class="section-num">01</span>The Cardiovascular Cliff</a></li>
 <li><a href="#lipid-shifts"><span class="section-num">02</span>Lipid Profile Shifts</a></li>
 <li><a href="#endothelial-function"><span class="section-num">03</span>Endothelial Resilience</a></li>
 <li><a href="#metabolic-markers"><span class="section-num">04</span>Advanced Lab Markers</a></li>
 <li><a href="#exercise-medicine"><span class="section-num">05</span>Exercise as Medicine</a></li>
 </ul>
 </nav>

 <!-- Module Connection -->
 <div class="module-connection">
 <div class="connection-text">
 <p>In previous lessons, we explored the impact of estrogen decline on the brain and skin. Now, we turn to the <strong>most critical health priority</strong> in the Evolve phase: the cardiovascular system, where the loss of hormonal protection creates a rapid shift in physiological risk.</p>
 </div>
 </div>

 <!-- Welcome Box -->
 <div class="welcome-box">
 <h3>Welcome, Specialist</h3>
 <p>As women move into the 'Evolve' (post-menopausal) phase, their risk for cardiovascular disease (CVD) doesn't just increase‚Äîit accelerates. For many years, estrogen acted as a biological "shield" for the heart and blood vessels. In this lesson, we will master the clinical nuances of the post-estrogen heart, moving beyond basic cholesterol panels to a sophisticated, functional assessment of vascular health.</p>
 </div>

 <!-- Learning Objectives -->
 <div class="objectives-box">
 <p class="box-label">Learning Objectives</p>
 <ul>
 <li>Analyze why CVD risk accelerates rapidly following the final menstrual period (FMP).</li>
 <li>Identify the specific shifts in LDL, ApoB, and HDL quality during the Evolve phase.</li>
 <li>Explain the mechanism by which declining estrogen impairs nitric oxide production and endothelial function.</li>
 <li>Evaluate the clinical utility of advanced markers including ApoB, Lp(a), and hs-CRP.</li>
 <li>Design cardiovascular conditioning protocols tailored for long-term heart protection.</li>
 </ul>
 </div>

 <h2 id="cardiovascular-cliff">The 'Cardiovascular Cliff': Post-Menopausal Acceleration</h2>
 <p>In the United States, cardiovascular disease remains the <span class="highlight">leading cause of death for women</span>, yet many women in their 40s and 50s are more concerned about breast cancer. Statistics show that <span class="stat-highlight">1 in 3 women will die of CVD</span>, compared to 1 in 31 from breast cancer. The transition into the 'Evolve' phase marks what clinicians call the "Cardiovascular Cliff."</p>

 <p>Before menopause, women generally have a lower risk of heart disease than men of the same age. However, within 10 years of the final menstrual period, that gap closes rapidly. This isn't just due to chronological aging; it is a direct consequence of <span class="highlight">estrogen withdrawal</span> affecting lipid metabolism, fat distribution, and vascular elasticity.</p>

 <div class="coach-tip">
 <span class="tip-label">Coach Tip: Addressing Imposter Syndrome</span>
 <p>Specialists often feel intimidated by "heart health" topics. Remember: you aren't a cardiologist, but you are a <strong>risk reduction architect</strong>. By helping a client understand her ApoB or hs-CRP, you are providing the data she needs to have a higher-level conversation with her doctor. This advocacy is worth $150-$300+ per consultation in a high-impact practice.</p>
 </div>

 <h2 id="lipid-shifts">Analyzing Lipid Profile Shifts</h2>
 <p>The transition to post-menopause is associated with a pro-atherogenic shift in the lipid profile. It is no longer enough to look at "Total Cholesterol" or even "LDL-C." We must look at the <em>composition</em> and <em>particle count</em> of these lipids.</p>

 <table class="data-table">
 <thead>
 <tr>
 <th>Marker</th>
 <th>Typical Shift in 'Evolve' Phase</th>
 <th>Clinical Significance</th>
 </tr>
 </thead>
 <tbody>
 <tr>
 <td><strong>LDL-Cholesterol</strong></td>
 <td>Increases by 10-15%</td>
 <td>Higher volume of potentially plaque-forming cholesterol.</td>
 </tr>
 <tr>
 <td><strong>Triglycerides</strong></td>
 <td>Significant Increase</td>
 <td>Reflects worsening insulin sensitivity and liver fat.</td>
 </tr>
 <tr>
 <td><strong>HDL-Cholesterol</strong></td>
 <td>May stay same or decrease</td>
 <td>"Quality" often decreases; it becomes less effective at clearing plaque.</td>
 </tr>
 <tr>
 <td><strong>ApoB</strong></td>
 <td>Sharp Increase</td>
 <td>Reflects the total number of atherogenic particles (most accurate risk marker).</td>
 </tr>
 </tbody>
 </table>

 <p>A critical nuance in the Evolve phase is the change in <span class="highlight">HDL functionality</span>. While we used to call HDL "good cholesterol," research now shows that in the absence of estrogen, HDL can become "pro-inflammatory," meaning it loses its ability to protect the arteries and may even contribute to oxidative stress.</p>

 <div class="case-study">
 <div class="case-study-header">
 <div class="case-study-icon">üë§</div>
 <div>
 <p class="title">Case Study: Linda, Age 54</p>
 <p class="subtitle">"Healthy" but High Risk</p>
 </div>
 </div>
 <div class="case-study-content">
 <div class="patient-profile">
 <p><strong>Profile:</strong> Linda is 3 years post-menopausal. Her GP told her her cholesterol was "fine" because her LDL was 120 mg/dL and HDL was 65 mg/dL.</p>
 <p><strong>The Deep Dive:</strong> Linda's Specialist ordered an <strong>ApoB</strong> and <strong>Lp(a)</strong> test. Her ApoB was 115 mg/dL (High Risk) and her Lp(a) was 140 nmol/L (Genetically High). Despite "normal" basic labs, Linda was on the fast track for a cardiac event.</p>
 <p><strong>Outcome:</strong> Linda started a PHASE-aligned protocol focusing on high-fiber intake (to clear bile) and specific Zone 2 cardio. She took this data to a preventive cardiologist for early intervention.</p>
 </div>
 </div>
 </div>

 <h2 id="endothelial-function">Endothelial Function and the Nitric Oxide Connection</h2>
 <p>The endothelium is the thin layer of cells lining our blood vessels. Think of it as the "teflon coating" of the arteries. Estrogen is a potent stimulator of <span class="highlight">Nitric Oxide (NO)</span>, a molecule that tells blood vessels to relax and dilate (vasodilation).</p>

 <p>When estrogen levels drop in the Evolve phase:</p>
 <ul>
 <li><strong>Nitric Oxide production plummets:</strong> Vessels become "stiffer" and less responsive.</li>
 <li><strong>Blood Pressure Rises:</strong> Stiffer pipes lead to higher pressure (systolic hypertension).</li>
 <li><strong>Vascular Inflammation:</strong> Without NO protection, the vessel walls are more easily damaged by circulating LDL particles.</li>
 </ul>

 <div class="coach-tip">
 <span class="tip-label">Coach Tip: The "Stiff Pipe" Analogy</span>
 <p>Explain this to clients using a garden hose analogy. "In your 30s, your arteries were like a flexible rubber hose. In the Evolve phase, they can become more like a brittle plastic pipe. We use nutrition and exercise to keep that hose flexible and resilient."</p>
 </div>

 <h2 id="metabolic-markers">Metabolic Markers for the 'Evolve' Roadmap</h2>
 <p>To truly assess risk in post-menopause, the PHASE Framework‚Ñ¢ recommends looking at the following advanced biomarkers:</p>

 <h3>1. Apolipoprotein B (ApoB)</h3>
 <p>ApoB is the primary protein found on all potentially atherogenic (plaque-forming) particles. While LDL-C measures the <em>weight</em> of cholesterol, ApoB measures the <em>number</em> of particles. Think of it as counting the number of cars on the highway rather than the weight of the passengers inside. <span class="stat-highlight">ApoB is a superior predictor of risk than LDL-C alone.</span></p>

 <h3>2. Lipoprotein(a) [Lp(a)]</h3>
 <p>This is a genetically determined marker. About 20% of the population has high Lp(a), which acts like "sticky LDL." It is highly inflammatory and significantly increases the risk of early heart attack or stroke. Every woman should have this tested <strong>at least once</strong> in her life, especially upon entering the Evolve phase.</p>

 <h3>3. High-Sensitivity CRP (hs-CRP)</h3>
 <p>A marker of systemic inflammation. In post-menopause, an elevated hs-CRP (above 2.0 mg/L) suggests that the vascular environment is "primed" for plaque buildup. It reflects the "fire" in the vessels.</p>

 <div class="coach-tip">
 <span class="tip-label">Coach Tip: Normal vs. Optimal</span>
 <p>Lab "normal" for hs-CRP is often anything under 3.0. In the PHASE Framework‚Ñ¢, we aim for <strong>Optimal</strong>, which is under 1.0 mg/L. Helping a client move from 2.8 to 0.8 through diet and stress management is a massive win for her longevity.</p>
 </div>

 <h2 id="exercise-medicine">Exercise as Medicine: Cardiovascular Conditioning</h2>
 <p>In the Evolve phase, exercise must be strategic. We are no longer just "burning calories"; we are <span class="highlight">remodeling the heart and vessels</span>.</p>

 <ul>
 <li><strong>Zone 2 Training (Low Intensity Steady State):</strong> 150-200 minutes per week. This improves mitochondrial health and helps clear lactate, supporting metabolic flexibility. It is the foundation of heart health.</li>
 <li><strong>HIIT (High Intensity Interval Training):</strong> 1 session per week (if recovered). Short bursts of high intensity help improve <em>stroke volume</em> (the amount of blood the heart pumps per beat) and arterial elasticity.</li>
 <li><strong>Resistance Training:</strong> 2-3 sessions per week. While often thought of for bones, muscle is a "metabolic sink" for glucose. By keeping blood sugar low, we prevent the "glycation" (sugar-coating) of LDL particles, making them less dangerous.</li>
 </ul>

 <div class="coach-tip">
 <span class="tip-label">Coach Tip: Practical Application</span>
 <p>For a client who is sedentary, don't start with HIIT. Start with a "Heart Health Walk" (Zone 2) for 20 minutes daily. As her specialist, you are building her <strong>aerobic base</strong> before adding the intensity of the Evolve phase deep dives.</p>
 </div>

 <!-- Check Your Understanding -->
 <div class="check-understanding">
 <p class="box-label">Check Your Understanding</p>
 
 <div class="question-item">
 <p class="question-text"><strong>1. Why is ApoB considered a better marker than LDL-C for post-menopausal women?</strong></p>
 <button class="reveal-btn">Reveal Answer</button>
 <div class="answer-text">ApoB measures the total number of atherogenic particles, whereas LDL-C only measures the mass of cholesterol. In the Evolve phase, particles often become smaller and more numerous, meaning a "normal" LDL-C can hide a dangerously high particle count (ApoB).</div>
 </div>

 <div class="question-item">
 <p class="question-text"><strong>2. What role does Nitric Oxide (NO) play in the cardiovascular system, and how does menopause affect it?</strong></p>
 <button class="reveal-btn">Reveal Answer</button>
 <div class="answer-text">Nitric Oxide is a vasodilator that keeps blood vessels flexible. Estrogen stimulates NO production. When estrogen declines in menopause, NO levels drop, leading to stiffer arteries and increased blood pressure.</div>
 </div>

 <div class="question-item">
 <p class="question-text"><strong>3. True or False: HDL always remains "protective" regardless of hormonal status.</strong></p>
 <button class="reveal-btn">Reveal Answer</button>
 <div class="answer-text">False. In the post-menopausal environment, HDL can lose its protective qualities and become pro-inflammatory, a phenomenon known as "HDL dysfunction."</div>
 </div>

 <div class="question-item">
 <p class="question-text"><strong>4. What is the recommended frequency for HIIT in the Evolve phase for heart health?</strong></p>
 <button class="reveal-btn">Reveal Answer</button>
 <div class="answer-text">The PHASE Framework‚Ñ¢ generally recommends 1 session per week of HIIT, provided the client has a solid Zone 2 aerobic base and is recovering well, to improve stroke volume and arterial elasticity.</div>
 </div>
 </div>

 <!-- Key Takeaways -->
 <div class="takeaways-box">
 <p class="box-label">Key Takeaways</p>
 <ul>
 <li><strong>CVD is the #1 Threat:</strong> Heart disease risk accelerates sharply after the final menstrual period due to the loss of estrogen's protective shield.</li>
 <li><strong>Look Beyond the Basics:</strong> Standard lipid panels often miss the pro-atherogenic shifts in particle count (ApoB) and genetic risk (Lp(a)).</li>
 <li><strong>Vascular Stiffness:</strong> Declining estrogen reduces Nitric Oxide, leading to endothelial dysfunction and rising blood pressure.</li>
 <li><strong>Inflammation Matters:</strong> Monitoring hs-CRP helps identify if the vascular system is in a pro-inflammatory state.</li>
 <li><strong>Strategic Movement:</strong> A combination of Zone 2 cardio, limited HIIT, and resistance training is the "gold standard" for post-menopausal heart protection.</li>
 </ul>
 </div>

 <!-- References -->
 <div class="references-box">
 <p class="box-label">References & Further Reading</p>
 <ol>
 <li>El Khoudary, S. R., et al. (2020). "Menopause Transition and Cardiovascular Disease Risk: Implications for Primary Prevention." <em>Circulation</em>.</li>
 <li>Samargandy, S., et al. (2021). "Lipoprotein(a) and Risk of Cardiovascular Disease in Women." <em>Journal of the American College of Cardiology</em>.</li>
 <li>Wellons, M., et al. (2012). "Early Menopause and Subsequent Cardiovascular Disease." <em>Archives of Internal Medicine</em>.</li>
 <li>Maki, P. M., et al. (2021). "The North American Menopause Society Position Statement on Management of Menopause." <em>Menopause</em>.</li>
 <li>Grundy, S. M., et al. (2019). "AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol." <em>Circulation</em>.</li>
 <li>Rosano, G. M., et al. (2007). "The Menopause and Cardiovascular Disease: Evidence-Based Approach." <em>Climacteric</em>.</li>
 </ol>
 </div>
</div>

<script>
document.querySelectorAll('.reveal-btn').forEach(button => {
 button.addEventListener('click', function() {
 const answer = this.nextElementSibling;
 if (answer && answer.classList.contains('answer-text')) {
 const isVisible = answer.style.display === 'block';
 answer.style.display = isVisible ? 'none' : 'block';
 this.textContent = isVisible ? 'Reveal Answer' : 'Hide Answer';
 }
 });
});
</script>

</body>
</html>